[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571327":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":37,"collaborators":10,"id":39,"slug":10,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Beijing Anlong Biopharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"The subjects received AL-001 ophthalmic injection",null,"Evaluate long-term safety and efficacy",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"AnlongBio","CONTACT","+86-010-80414166","info@anlongbio.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":10,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Chinese Academy of Medical Sciences & Peking Union Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":27,"coordinates":28},"Point",[29,30],116.39723,39.9075,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":35,"phoneExt":10,"email":36},"YouxinChen","+86-010-65296358","chenyouxinpumch@163.com",{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571327",false,"NCT06718816","Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD","A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)","Inclusion Criteria:\n\n* The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.\n* The subject or their legal representative agrees to participate in this study and signs a written ICF.\n* The subjects are willing and able to follow planned visits and procedures.\n\nExclusion Criteria:\n\n* None","ALL","50 Years",{"count":48,"type":49},21,"ESTIMATED","OBSERVATIONAL","This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.",[53],"Wet Age-related Macular Degeneration (wAMD)","2024-12-02",{"date":56,"type":57},"2024-12-05","ACTUAL",{"date":59,"type":49},"2024-12-09",{"date":61,"type":49},"2029-06-30",{"name":5,"class":6},1]